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forts for Geneva-Yaounde cooperation to train Cameroonian medical
geneticist thatmay serve as a usefulmodel for developinghealth profes-
sional education because it is easy, affordable with direct beneﬁts
(Gerber, 2005). In sum, neurogenomics in Egypt lags far behind that in
the better resourced of the world.1. Introduction
In the beginning of the twenty-ﬁrst century, the world celebrated
the ﬁftieth anniversary of the discovery of DNA. The discovery has led
to enormous amounts of new knowledge, including the fact that the
human genome has a physical size of 3 × 109 base pairs that encode
and regulate approximately 32,000 genes. It has also spawned new
ﬁelds, such as Genomics, which was born in Europe (Goetz, 2004),
and the sub-ﬁeld neurogenomics, which examines themolecularmech-
anisms and the interplay of thismolecular information and health inter-
ventions and environmental factors of neurological disorders. TheWest
has been able to advance neurogenomics, establishing high quality
research institutions and educating health care professionals to incor-
porate new knowledge into diagnosing and testing patients. Egypt,
however, has been far less able. The genetic research and services
disparity between developed countries and the developing ones, specif-
ically Egypt, is huge. In Egypt, as with other developing countries, geno-
mic research capabilities and basic genetic services are considerably
limited by infrastructure deﬁcits. Genetic screening, and counseling, is
common practice in theWest, but not so in Egypt and other developing
countries. Prenatal genetic screening for hemoglobin disorders, for
instance, exists in most developed countries, but not so in developing
world. Furthermore, the disparity in terms of genetically literate
healthcare professionals and cost of care is substantial (Skirton et al.,
2010; Thurston et al., 2007). In high-resource countries, the treatment
cost is covered by medical insurance, while in lower-income countries
the cost falls directly on families.). These gaps between developed and
developing countries have been discussed in detail by WHO expert
groups (World Health Organization, 1999, 2000, 2002) and others
(Alwan and Modell, 2003; James et al., 1998; Penchaszadeh, 2000;
Wonkam et al., 2006) who recommended several steps for developing
countries, including Egypt, that wish to incorporate molecular. This is an open access article under2. Why is neurogenomics more challenging to perform in Egypt?
There is no doubt that African populations have a complex evolu-
tionary history and hence display genetic diversity. But, currently little
is known about their genetic proﬁle. Basic biomedical research is the
cornerstone for medical development and discoveries but without re-
search facilities and clinical researchers, neurogenomics cannot advance
in Egypt. Likemost of low- andmiddle-income countries, Egypt is strug-
gling to establish affordable genetics capabilities and facing consider-
able obstacles in the process. For example, genetically deﬁned mouse
strains, (inbred, co-isogenic, cogenic, knockout and transgenic strains)
have become invaluable in research, especially for neurogenomics
because they can elucidate genetics vs. environment inﬂuences on a
wide variety of traits and offer the means to test multiple genetically
identical animals at one time. However, these strains are not available
in Egypt. Researchers must import them, which entails navigating a
very expensive and complicated process entailing a formidable bureau-
cracy and strict regulation. The work around is to use the fruit ﬂy Dro-
sophila melanogaster as an affordable model organism. Its advantages
for neurogenomics analysis include the fact that about 50% of human
genes have a Drosophila ortholog (Shulman et al., 2003). Moreover, be-
cause the life cycle of the ﬂy is rapid, with the possibility of breeding
thousands of genetically identical ﬂies in less than amonth, researchers
can conduct neurogenomics research for less cost and short time. Fur-
ther, D. melanogaster expresses complex patterns of behavior (Hall,
1994; Sokolowski, 2001),which enables researchers to explore the phe-
notype characteristics of genes. A superb genetic database of informa-
tion has been collected over more than 80 years (Asburner et al.,
2004) and its fully sequenced genome has many tools and a database
(see http://ﬂybase.bio.indiana.edu/ for database of the Drosophila
genome and related tools) that enables researchers to access genetic
data easily for less cost. Another cheap and affordablemodel to study ge-
netics is the nematode Caenorhabditis elegans that has a rapid growth rate
with small size of genome (100 Mbases) (Fire et al., 1998). However,
without access to the mouse strains noted above and related tools, the
Egyptian scientiﬁc community cannot develop a goodneurogenomics da-
tabase and the informatics tools requisite to identifying genetic variants
implicated in neurological disorders, or embark on discovery andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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a database of genes, genetic polymorphisms and phenotypes related to
neurological disorders in order to then translate the information for clin-
ical beneﬁt. That is, the geneticmapping of Arab andAfrican population is
essential for the identiﬁcation and interpretation of genetic variation in
patients with speciﬁc neurological diseases in certain sub populations.
At present, there is no any such initiative in Egypt and therefore no avail-
able data on familial types of diseases like PD (Parkinson's disease).
Further while quantitative genetics can render valuable information to
the neuroscientist's arsenal and may greatly enhance our understanding
of the neurogenomics of many neurological disorders, Egypt's lack of
resources hampers our ability to conduct important quantitative experi-
ments, such as quantitative trait loci (QTL). Therefore, our research capac-
ity is severely constrained. Egypt, like some of its sister Arab countries, is
now using next generation sequencing (NGS), but to be able to advance
neurogenomics in Egypt, it is imperative to establish an Arab and an
African population speciﬁc NGS database on neurological disorders
(Fokkema et al., 2011). We need to encourage researchers to conduct
association studies that focus on the Egyptian population in order to
provide powerful tools to identify genetic components in neuro-
psychiatric disorders. Indeed, open databases are crucial to enabling our
neurogenomics research in Egypt. However, ﬁnancial constraints pose a
formidable obstacle to start such an initiative. The Gulf States and
oil-rich countries allot only 0.1–2.5% of gross national product (GNP)
for research and development (Giles, 2006). Egypt's ability to conduct
neurogenomics research and advance clinical neurogenomics can only
be done if greater funding is made available and the current system for
importing genetically deﬁnedmouse strains for basic researchmade sim-
pler and ﬁnancially feasible. Otherwise, advancing biomedical basic
research will suffer and may ultimately not be possible. The pace of
neurogenomics application in Egypt, for the reasons discussed above, is
quite slow. In high-resource countries, new genetic knowledge has
been incorporated into medical curriculum, in Europe, by 1970–1980
(Brunner, 2000; Goetz, 2004; Dahl, 2010; Orstavik, 2001), and in the
U.S. as early as 1955 (Waelsch and Nitowsky, 1990), with the majority
of USmedical schools (77% of the 112 schools) teachingmedical genetics
(Childs et al., 1981; Thurston et al., 2007). In Egypt where there is no
uniform medical curriculum across all 22 Egyptian medical schools, it
is hard to know to what extent medical genetics and neurogenomics
are taught. Therefore, it is not surprising that the need for “genetically
literate” healthcare professionals is low (Feero et al., 2014; Korf, 2002;
Stephenson, 1997; Skirton et al., 2010; Thurston et al., 2007). Apart
from the constrains discussed above, substandard clinical training
(Skirton et al., 2010; Thurston et al., 2007), and the fact that health
care professionals do not view such knowledge as clinically relevant
serves to maintain this unfortunate state (Kemper et al., 2010;
Phimister et al., 2012). Further, limited availability of competent
neurogenomics teaching faculty, and a providers' preference for clinical
specialties over basic biomedical specialties contribute to this deﬁcit
(Korf, 2002). High quality educational programs are needed to produce
well-trained medical geneticists.
3. Hopes and perspectives
Understanding the neurogenomics of Egyptian population will
lead to our understanding of African genomic variation, which in
turn will be an invaluable resource for scientists across the world.
It is crucial to recognize that the needs and priorities in developing
countries are wholly different to that those in developed countries.
Knowledge and skill commensurate with research and technological
advances are necessary to establishing neurogenomics research.
High quality research can ultimately lead to discoveries that trans-
late into new knowledge about disorders, new diagnostics, new
therapeutics and even prevention strategies. Without high quality
education at all levels, including medical schools and other
healthcare professional training programs, neither research norclinical neurogenomics care can advance in Egypt. Preparing
tomorrow's doctors to appropriate practice clinical neurogenomics
in Egypt requires assessing identifying the core neurogenomics
knowledge and skill set (Harden et al., 1999; Smith, 2009; Korf
et al., 2014). It also requires continuous evaluation of whether edu-
cational programs achieve their objectives (Gaff et al., 2007). These
programs should integrate the principles and application of medical
neurogenomics and genetics into undergraduate medical curricula
with many emphases on clinical practice. Physicians need to be
aware of, for example, common neurological disorders, such as epi-
lepsy, dementia, and neuromuscular disorders, be able to identify
when genetic components are present and master how to diagnose
their overlapping signs and symptoms. For instance, Dravet syn-
drome is rare catastrophic infantile epilepsy that ends with SUDEP
(sudden unexpected death in epilepsy) and identifying its genetic
defect enables physicians to treat with anticonvulsants. To achieve
educational goals, medical societies and advocacy groups in Egypt
should work together to educate primary care professionals and pa-
tients to value the neurogenomics tools for diagnosis and treatment.
In sum, to advance neurogenomics in Africa and Egypt, the overall
goal of scientiﬁc community should be focused capacity building and
networking. I recommend the following for introducing and advancing
neurogenomics services in developing countries: 1) Establish educa-
tional resources and online free courses, 2) Disseminate of knowledge
and establish an African Journal of Human Genetics, 3) support and
incorporate neurogenomics advocacy, 4) effectively and efﬁciently
transfer technology, and 5) encourage collaborative neurogenomics
research.4. Conclusion
Neurogenomics information is essential for optimal patient care
(Institute of Medicine, 2012). It can be helpful in diagnosis, treatment
assessment, side effect prediction, and disease prevention as well as
preventing drug–drug interactions in some patients. We, as Egyptian
physicians, hope to have a clear conceptual framework for the applica-
tion of clinical neurogenomics, mainly towards prevention, diagnosis
andmanagement (Korf, 2013).Woefully, science in Egypt is not viewed
as a necessity and neurogenomics is not regarded as an important hu-
manitarian conquest or requisite. Therefore, there is a need to rearrange
our priorities in Egypt and establish policy initiatives to advance
neurogenetics research. Moreover, Egyptian policymakers, media and
the public need to work together to alleviate fears and concerns regard-
ing neurogenomics research and create a friendly neurogenomics
research environment with an acceptable legal, moral, ethical and cul-
tural framework. The fears and concerns regarding neurogenomics re-
search emerge from s a number of ethical challenges (Leng, 2002). For
example, there are several relevant unanswered questions including:
1) Is it possible for human subjects to consent using their biological
samples or genetic data regardless the aims of the research? 2) Do re-
search ethics committees have sufﬁcient knowledge and experience to
handle authorization of neurogenomics research? 3) Neurogenomics
research has the potential to medicalize normal human conditions and
disability i.e., will research may be used inappropriately to further
human development? 4) Will various devices used in neurogenomics
research to collect human subject data be used in ways that violate pri-
vacy?, and ﬁnally 5) Which research and applications will be funded
governmentally? How we can assess such research? Finally, there is a
pressingneed to address the aforementioned inequalities in order to de-
velop a common minimum standard of competencies among medical
professionals in developing countries. I hope that the neurogenomics
technologies will soon be applied in Egypt within clinical practice. This
will open thehorizon for a newera of data centric clinical practice. How-
ever, the question is still the same Are Egyptians prepared for this new
era yet?
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